司美格鲁肽片：以科学之名，64周平均减重16.6%

Core Viewpoint - Semaglutide, a GLP-1 receptor agonist, effectively aids in weight loss by enhancing insulin secretion, suppressing glucagon secretion, delaying gastric emptying, and increasing satiety, leading to reduced appetite and food intake [4][6]. Mechanism of Action - Semaglutide activates specific neurons in the hypothalamus, signaling a feeling of fullness before eating, which is particularly effective in treating obesity [5]. - The appetite-reducing effects of semaglutide occur through three main mechanisms: - Central action: It acts on the hypothalamus to reduce appetite and hunger [6]. - Gastrointestinal action: It slows gastric emptying, increasing feelings of fullness [6]. - Altered food preferences: Patients show a significant decrease in preference and intake of high-fat, fried, or sweet foods [6]. Clinical Efficacy - In clinical trials, patients using semaglutide for 68 weeks lost an average of 15.3 kg, compared to 2.6 kg in the placebo group, with a weight reduction rate of 14.9% versus 2.4% [4]. - The approval of semaglutide for weight management in China is expected to provide a breakthrough solution for overweight and obese patients, enhancing access to effective treatment [13]. Regulatory Approvals - In January 2024, oral semaglutide (Rybelsus) was approved in China for treating type 2 diabetes, marking the first oral GLP-1 receptor agonist approved in the country [9]. - On June 25, 2024, the NMPA approved Wegovy, a semaglutide injection for long-term weight management in China [11]. - The approval of oral semaglutide in the U.S. in December 2025 for weight management and cardiovascular risk reduction signifies a new phase in weight loss medication competition [15][16]. Clinical Trial Data - The OASIS clinical trial demonstrated that daily administration of 25 mg oral semaglutide resulted in an average weight loss of 16.6% over 64 weeks, comparable to the 2.4 mg weekly injection [17]. - Approximately one-third of participants achieved a weight loss of 20% or more, addressing previous concerns about the efficacy of oral GLP-1 treatments [17].